{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["MD simulations", "VEGFR-2 inhibitors", "anti-proliferative", "apoptosis", "immunomodulation", "nicotinamide"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36234734", "DateCompleted": {"Year": "2022", "Month": "10", "Day": "17"}, "DateRevised": {"Year": "2022", "Month": "10", "Day": "19"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "21"}], "Language": ["eng"], "ELocationID": ["6203", "10.3390/molecules27196203"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "19", "PubDate": {"Year": "2022", "Month": "Sep", "Day": "21"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies.", "Abstract": {"AbstractText": ["Four new nicotinamide-based derivatives were designed as antiangiogenic VEGFR-2 inhibitors. The congeners were synthesized possessing the pharmacophoric essential features to bind correctly with the VEGFR-2 active pocket. All members were evaluated for their cytotoxic and VEGFR-2 inhibitory potentialities. Compound <b>6</b> was the most potent showingIC<sub>50</sub> values of 9.3 \u00b1 0.02 and 7.8 \u00b1 0.025 \u00b5M against HCT-116 and HepG-2 cells, respectively, and IC<sub>50</sub> of 60.83 nM regarding VEGFR-2 enzyme inhibition. Compound <b>6</b> arrested the growth of HCT-116 cells at the pre-G1 and G2-M phases. Further, it induced both early and late apoptosis. Additionally, compound <b>6</b> caused a significant decrease in TNF-<i>\u03b1</i> and IL6 by 66.42% and 57.34%, respectively. The considered compounds had similar docking performances to that of sorafenib against the VEGFR-2 (PDB ID: 2OH4). The correct binding of compound <b>6</b> with VEGFR-2 was validated using MD simulations, and MM-GPSA calculations."]}, "AuthorList": [{"Identifier": ["0000-0002-2546-8035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0003-3709-1930"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": ["0000-0002-8146-993X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Khalifa", "ForeName": "Mohamed M", "Initials": "MM"}, {"Identifier": ["0000-0001-9759-8907"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Ibrahim", "ForeName": "Albaraa", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Mehany", "ForeName": "Ahmed B M", "Initials": "ABM"}, {"Identifier": ["0000-0003-0637-4268"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Gobaara", "ForeName": "Ibraheem M M", "Initials": "IMM"}, {"Identifier": ["0000-0001-6489-6035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Bshra A", "Initials": "BA"}, {"Identifier": ["0000-0001-6996-4017"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt."}, {"Identifier": [], "Affiliation": "School of Biotechnology, Badr University in Cairo, Badr City 11829, Egypt."}], "LastName": "Eldehna", "ForeName": "Wagdy M", "Initials": "WM"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "El-Zahabi", "ForeName": "Mohamed Ayman", "Initials": "MA"}], "GrantList": [{"GrantID": "PNURSP2022R142", "Agency": "Princess Nourah bint Abdulrahman University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-6"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "9ZOQ3TZI87", "NameOfSubstance": "Sorafenib"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Interleukin-6"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Sorafenib"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Tumor Necrosis Factor-alpha"}, {"QualifierName": [], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Eissa I.H., Dahab M.A., Ibrahim M.K., Alsaif N.A., Alanazi A., Eissa S.I., Mehany A.B., Beauchemin A.M. Design and discovery of new antiproliferative 1, 2, 4-triazin-3 (2H)-ones as tubulin polymerization inhibitors targeting colchicine binding site. Bioorganic Chem. 2021;112:104965. doi: 10.1016/j.bioorg.2021.104965.", "ArticleIdList": ["10.1016/j.bioorg.2021.104965", "34020238"]}, {"Citation": "Modi S.J., Kulkarni V.M. Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: Medicinal chemistry perspective. Med. Drug Discov. 2019;2:100009. doi: 10.1016/j.medidd.2019.100009.", "ArticleIdList": ["10.1016/j.medidd.2019.100009"]}, {"Citation": "Modi S.J., Kulkarni V.M. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-\u03b2 induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Eur. J. Med. Chem. 2020;207:112851. doi: 10.1016/j.ejmech.2020.112851.", "ArticleIdList": ["10.1016/j.ejmech.2020.112851", "33002846"]}, {"Citation": "Sana S., Reddy V.G., Bhandari S., Reddy T.S., Tokala R., Sakla A.P., Bhargava S.K., Shankaraiah N. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. Eur. J. Med. Chem. 2020;200:112457. doi: 10.1016/j.ejmech.2020.112457.", "ArticleIdList": ["10.1016/j.ejmech.2020.112457", "32422489"]}, {"Citation": "Claesson-Welsh L., Welsh M. VEGFA and tumour angiogenesis. J. Intern. Med. 2013;273:114\u2013127. doi: 10.1111/joim.12019.", "ArticleIdList": ["10.1111/joim.12019", "23216836"]}, {"Citation": "Suleimen Y.M., Metwaly A.M., Mostafa A.E., Elkaeed E.B., Liu H.-W., Basnet B.B., Suleimen R.N., Ishmuratova M.Y., Turdybekov K.M., van He\u0441ke K. Isolation Crystal Structure, and In Silico Aromatase Inhibition Activity of Ergosta-5, 22-dien-3\u03b2-ol from the Fungus Gyromitra esculenta. J. Chem. 2021;2021:5529786. doi: 10.1155/2021/5529786.", "ArticleIdList": ["10.1155/2021/5529786"]}, {"Citation": "El-Adl K., Sakr H.M., Yousef R.G., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A., Abulkhair H.S., Eissa I.H. Discovery of new quinoxaline-2 (1h)-one-based anticancer agents targeting vegfr-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorganic Chem. 2021;114:105105. doi: 10.1016/j.bioorg.2021.105105.", "ArticleIdList": ["10.1016/j.bioorg.2021.105105", "34175720"]}, {"Citation": "Alanazi M.M., Mahdy H.A., Alsaif N.A., Obaidullah A.J., Alkahtani H.M., Al-Mehizia A.A., Alsubaie S.M., Dahab M.A., Eissa I.H. New bis ([1, 2, 4] triazolo)[4, 3-a: 3\u2032, 4\u2032-c] quinoxaline derivatives as vegfr-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Bioorganic Chem. 2021;112:104949. doi: 10.1016/j.bioorg.2021.104949.", "ArticleIdList": ["10.1016/j.bioorg.2021.104949", "34023640"]}, {"Citation": "Oguro Y., Cary D.R., Miyamoto N., Tawada M., Iwata H., Miki H., Hori A., Imamura S. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: Discovery of [1, 2, 4] triazolo [1, 5-a] pyridine derivatives with slow dissociation kinetics. Biorg. Med. Chem. 2013;21:4714\u20134729. doi: 10.1016/j.bmc.2013.04.042.", "ArticleIdList": ["10.1016/j.bmc.2013.04.042", "23755884"]}, {"Citation": "AbdelHaleem A., Mansour A.O., AbdelKader M., Arafa R.K. Selective VEGFR-2 inhibitors: Synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling. Bioorganic Chem. 2020;103:104222. doi: 10.1016/j.bioorg.2020.104222.", "ArticleIdList": ["10.1016/j.bioorg.2020.104222", "32889383"]}, {"Citation": "Gu W., Dai Y., Qiang H., Shi W., Liao C., Zhao F., Huang W., Qian H. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. Bioorganic Chem. 2017;72:116\u2013122. doi: 10.1016/j.bioorg.2017.04.001.", "ArticleIdList": ["10.1016/j.bioorg.2017.04.001", "28411406"]}, {"Citation": "Yousef R.G., Ibrahim A., Khalifa M.M., Eldehna W.M., Gobaara I.M., Mehany A.B., Elkaeed E.B., Alsfouk A.A., Metwaly A.M., Eissa I.H. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: Virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J. Enzym. Inhib. Med. Chem. 2022;37:1389\u20131403. doi: 10.1080/14756366.2022.2070744.", "ArticleIdList": ["10.1080/14756366.2022.2070744", "PMC9116259", "35577416"]}, {"Citation": "El-Metwally S.A., Abou-El-Regal M.M., Eissa I.H., Mehany A.B., Mahdy H.A., Elkady H., Elwan A., Elkaeed E.B. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorganic Chem. 2021;112:104947. doi: 10.1016/j.bioorg.2021.104947.", "ArticleIdList": ["10.1016/j.bioorg.2021.104947", "33964580"]}, {"Citation": "Elkady H., Elwan A., El-Mahdy H.A., Doghish A.S., Ismail A., Taghour M.S., Elkaeed E.B., Eissa I.H., Dahab M.A., Mahdy H.A. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:397\u2013410. doi: 10.1080/14756366.2021.2015343.", "ArticleIdList": ["10.1080/14756366.2021.2015343", "PMC8725875", "34961427"]}, {"Citation": "El-Helby A.G.A., Sakr H., Eissa I.H., Abulkhair H., Al-Karmalawy A.A., El-Adl K. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors. Arch. Pharm. 2019;352:1900113. doi: 10.1002/ardp.201900113.", "ArticleIdList": ["10.1002/ardp.201900113", "31448458"]}, {"Citation": "Saleh N.M., Abdel-Rahman A.A.H., Omar A.M., Khalifa M.M., El-Adl K. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking. Arch. Pharm. 2021;354:2100085. doi: 10.1002/ardp.202100085.", "ArticleIdList": ["10.1002/ardp.202100085", "33948983"]}, {"Citation": "Eissa I.H., Ibrahim M.K., Metwaly A.M., Belal A., Mehany A.B., Abdelhady A.A., Elhendawy M.A., Radwan M.M., ElSohly M.A., Mahdy H.A. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorganic Chem. 2021;107:104532. doi: 10.1016/j.bioorg.2020.104532.", "ArticleIdList": ["10.1016/j.bioorg.2020.104532", "33334586"]}, {"Citation": "Alesawy M.S., Ibrahim M.K., Eissa I.H., El-Adl K. Design, synthesis, in silico admet, docking, and antiproliferative evaluations of [1, 2, 4] triazolo [4, 3-c] quinazolines as classical DNA intercalators. Arch. Pharm. 2022;355:2100412. doi: 10.1002/ardp.202100412.", "ArticleIdList": ["10.1002/ardp.202100412", "35014084"]}, {"Citation": "Parmar D.R., Soni J.Y., Guduru R., Rayani R.H., Kusurkar R.V., Vala A.G., Talukdar S.N., Eissa I.H., Metwaly A.M., Khalil A. Discovery of new anticancer thiourea-azetidine hybrids: Design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorganic Chem. 2021;115:105206. doi: 10.1016/j.bioorg.2021.105206.", "ArticleIdList": ["10.1016/j.bioorg.2021.105206", "34339975"]}, {"Citation": "Abdelgawad M.A., El-Adl K., El-Hddad S.S., Elhady M.M., Saleh N.M., Khalifa M.M., Khedr F., Alswah M., Nayl A.A., Ghoneim M.M., et al. Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2, 4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPAR\u03b3 Agonists. Pharmaceuticals. 2022;15:226. doi: 10.3390/ph15020226.", "ArticleIdList": ["10.3390/ph15020226", "PMC8880361", "35215339"]}, {"Citation": "Yousef R.G., Sakr H.M., Eissa I.H., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A., Abulkhair H.S., El-Adl K. New quinoxaline-2 (1 H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J. Chem. 2021;45:16949\u201316964. doi: 10.1039/D1NJ02509K.", "ArticleIdList": ["10.1039/D1NJ02509K", "34175720"]}, {"Citation": "Alanazi M.M., Eissa I.H., Alsaif N.A., Obaidullah A.J., Alanazi W.A., Alasmari A.F., Albassam H., Elkady H., Elwan A. Design, synthesis, docking, admet studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as vegfr-2 inhibitors and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2021;36:1760\u20131782. doi: 10.1080/14756366.2021.1956488.", "ArticleIdList": ["10.1080/14756366.2021.1956488", "PMC8344243", "34340610"]}, {"Citation": "Ran F., Li W., Qin Y., Yu T., Liu Z., Zhou M., Liu C., Qiao T., Li X., Yousef R.G. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation. Oxidative Med. Cell. Longev. 2021;2021:8321400. doi: 10.1155/2021/8321400.", "ArticleIdList": ["10.1155/2021/8321400", "PMC8568530", "34745424"]}, {"Citation": "Sousa S.F., Fernandes P.A., Ramos M.J. Protein\u2013ligand docking: Current status and future challenges. Proteins Struct. Funct. Bioinform. 2006;65:15\u201326. doi: 10.1002/prot.21082.", "ArticleIdList": ["10.1002/prot.21082", "16862531"]}, {"Citation": "Hansson T., Oostenbrink C., van Gunsteren W. Molecular dynamics simulations. Curr. Opin. Struct. Biol. 2002;12:190\u2013196. doi: 10.1016/S0959-440X(02)00308-1.", "ArticleIdList": ["10.1016/S0959-440X(02)00308-1", "11959496"]}, {"Citation": "Liu P., Lu J., Yu H., Ren N., Lockwood F.E., Wang Q.J. Lubricant shear thinning behavior correlated with variation of radius of gyration via molecular dynamics simulations. J. Chem. Phys. 2017;147:084904. doi: 10.1063/1.4986552.", "ArticleIdList": ["10.1063/1.4986552", "28863549"]}, {"Citation": "Kumar K., Anbarasu A., Ramaiah S. Molecular docking and molecular dynamics studies on \u03b2-lactamases and penicillin binding proteins. Mol. BioSystems. 2014;10:891\u2013900. doi: 10.1039/C3MB70537D.", "ArticleIdList": ["10.1039/C3MB70537D", "24503740"]}, {"Citation": "Sun H., Li Y., Shen M., Tian S., Xu L., Pan P., Guan Y., Hou T. Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Phys. Chem. Chem. Phys. 2014;16:22035\u201322045. doi: 10.1039/C4CP03179B.", "ArticleIdList": ["10.1039/C4CP03179B", "25205360"]}, {"Citation": "Xia X., Maliski E.G., Gallant P., Rogers D. Classification of kinase inhibitors using a Bayesian model. J. Med. Chem. 2004;47:4463\u20134470. doi: 10.1021/jm0303195.", "ArticleIdList": ["10.1021/jm0303195", "15317458"]}, {"Citation": "BIOVIA QSAR, ADMET and Predictive Toxicology.  [(accessed on 1 May 2020)].  Available online:  https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/qsar-admet-and-predictive-toxicology.html."}, {"Citation": "Venkatapathy R., Wang N.C.Y., Martin T.M., Harten P.F., Young D. Structure\u2013Activity Relationships for Carcinogenic Potential. Gen. Appl. Syst. Toxicol. 2009 doi: 10.1002/9780470744307.gat079.", "ArticleIdList": ["10.1002/9780470744307.gat079"]}, {"Citation": "Goodrnan G., Wilson R. Comparison of the dependence of the TD50 on maximum tolerated dose for mutagens and nonmutagens. Risk Anal. 1992;12:525\u2013533. doi: 10.1111/j.1539-6924.1992.tb00709.x.", "ArticleIdList": ["10.1111/j.1539-6924.1992.tb00709.x", "1480798"]}, {"Citation": "Council N.R. Issues in Risk Assessment. National Academies Press (US); Washington, DC, USA: 1993. Correlation Between Carcinogenic Potency and the Maximum Tolerated Dose: Implications for Risk Assessment."}, {"Citation": "Diaza R.G., Manganelli S., Esposito A., Roncaglioni A., Manganaro A., Benfenati E. Comparison of in silico tools for evaluating rat oral acute toxicity. SAR QSAR Environ. Res. 2015;26:1\u201327. doi: 10.1080/1062936X.2014.977819.", "ArticleIdList": ["10.1080/1062936X.2014.977819", "25567032"]}, {"Citation": "Pizzo F., Benfenati E. In Silico Methods for Predicting Drug Toxicity. Springer; Berlin/Heidelberg, Germany: 2016. In silico models for repeated-dose toxicity (RDT): Prediction of the no observed adverse effect level (NOAEL) and lowest observed adverse effect level (LOAEL) for drugs; pp. 163\u2013176.", "ArticleIdList": ["27311467"]}, {"Citation": "Venkatapathy R., Moudgal C.J., Bruce R.M. Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction. J. Chem. Inf. Comput. Sci. 2004;44:1623\u20131629. doi: 10.1021/ci049903s.", "ArticleIdList": ["10.1021/ci049903s", "15446819"]}, {"Citation": "Chaitra G., Rohini R. Synthesis and biological activities of [1, 3]-oxazine derivatives. Der Pharma Chem. 2018;10:96\u2013101."}, {"Citation": "Eldehna W.M., Al-Rashood S.T., Al-Warhi T., Eskandrani R.O., Alharbi A., el Kerdawy A.M. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3\u03b2 inhibitors targeting breast cancer: Design, synthesis, biological evaluation, and in silico studies. J. Enzym. Inhib. Med. Chem. 2021;36:270\u2013285. doi: 10.1080/14756366.2020.1862101.", "ArticleIdList": ["10.1080/14756366.2020.1862101", "PMC7751407", "33327806"]}, {"Citation": "Al-Sanea M.M., Al-Ansary G.H., Elsayed Z.M., Maklad R.M., Elkaeed E.B., Abdelgawad M.A., Bukhari S.N.A., Abdel-Aziz M.M., Suliman H., Eldehna W.M. Development of 3-methyl/3-(morpholinomethyl) benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. J. Enzym. Inhib. Med. Chem. 2021;36:987\u2013999. doi: 10.1080/14756366.2021.1915302.", "ArticleIdList": ["10.1080/14756366.2021.1915302", "PMC8128204", "33985397"]}, {"Citation": "Abou-Seri S.M., Eldehna W.M., Ali M.M., el Ella D.A.A. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. Eur. J. Med. Chem. 2016;107:165\u2013179. doi: 10.1016/j.ejmech.2015.10.053.", "ArticleIdList": ["10.1016/j.ejmech.2015.10.053", "26590508"]}, {"Citation": "Wang J., Lenardo M.J. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J. Cell Sci. 2000;113:753\u2013757. doi: 10.1242/jcs.113.5.753.", "ArticleIdList": ["10.1242/jcs.113.5.753", "10671365"]}, {"Citation": "Eldehna W.M., Hassan G.S., Al-Rashood S.T., Al-Warhi T., Altyar A.E., Alkahtani H.M., Almehizia A.A., Abdel-Aziz H.A. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J. Enzym. Inhib. Med. Chem. 2019;34:322\u2013332. doi: 10.1080/14756366.2018.1547286.", "ArticleIdList": ["10.1080/14756366.2018.1547286", "PMC6366416", "30722708"]}, {"Citation": "Lo K.K.-W., Lee T.K.-M., Lau J.S.-Y., Poon W.-L., Cheng S.-H. Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorg. Chem. 2008;47:200\u2013208. doi: 10.1021/ic701735q.", "ArticleIdList": ["10.1021/ic701735q", "18067284"]}, {"Citation": "Sabt A., Abdelhafez O.M., El-Haggar R.S., Madkour H.M., Eldehna W.M., El-Khrisy E.E.-D.A., Abdel-Rahman M.A., Rashed L.A. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: Synthesis, in vitro biological evaluation, and QSAR studies. J. Enzym. Inhib. Med. Chem. 2018;33:1095\u20131107. doi: 10.1080/14756366.2018.1477137.", "ArticleIdList": ["10.1080/14756366.2018.1477137", "PMC6022226", "29944015"]}, {"Citation": "Suleimen Y.M., Jose R.A., Suleimen R.N., Arenz C., Ishmuratova M., Toppet S., Dehaen W., Alsfouk A.A., Elkaeed E.B., Eissa I.H. Isolation and In Silico Anti-SARS-CoV-2 Papain-Like Protease Potentialities of Two Rare 2-Phenoxychromone Derivatives from Artemisia spp. Molecules. 2022;27:1216. doi: 10.3390/molecules27041216.", "ArticleIdList": ["10.3390/molecules27041216", "PMC8879996", "35209006"]}, {"Citation": "Alanazi M.M., Elwan A., Alsaif N.A., Obaidullah A.J., Alkahtani H.M., Al-Mehizia A.A., Alsubaie S.M., Taghour M.S., Eissa I.H. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: Design, synthesis, and in silico studies. J. Enzym. Inhib. Med. Chem. 2021;36:1732\u20131750. doi: 10.1080/14756366.2021.1945591.", "ArticleIdList": ["10.1080/14756366.2021.1945591", "PMC8330740", "34325596"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Alsfouk A.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. New anticancer theobromine derivative targeting egfrwt and egfrt790m: Design, semi-synthesis, in silico, and in vitro anticancer studies. Molecules. 2022;27:5859. doi: 10.3390/molecules27185859.", "ArticleIdList": ["10.3390/molecules27185859", "PMC9500845", "36144596"]}, {"Citation": "Jo S., Kim T., Iyer V.G., Im W. CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. 2008;29:1859\u20131865. doi: 10.1002/jcc.20945.", "ArticleIdList": ["10.1002/jcc.20945", "18351591"]}, {"Citation": "Brooks B.R., Brooks C.L., III, Mackerell A.D., Jr., Nilsson L., Petrella R.J., Roux B., Won Y., Archontis G., Bartels C., Boresch S., et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 2009;30:1545\u20131614. doi: 10.1002/jcc.21287.", "ArticleIdList": ["10.1002/jcc.21287", "PMC2810661", "19444816"]}, {"Citation": "Lee J., Cheng X., Swails J.M., Yeom M.S., Eastman P.K., Lemkul J.A., Wei S., Buckner J., Jeong J.C., Qi Y., et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. J. Chem. Theory Comput. 2016;12:405\u2013413. doi: 10.1021/acs.jctc.5b00935.", "ArticleIdList": ["10.1021/acs.jctc.5b00935", "PMC4712441", "26631602"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "18"}, {"Year": "2022", "Month": "9", "Day": "12"}, {"Year": "2022", "Month": "9", "Day": "15"}, {"Year": "2022", "Month": "10", "Day": "14", "Hour": "2", "Minute": "24"}, {"Year": "2022", "Month": "10", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["36234734", "PMC9571953", "10.3390/molecules27196203", "molecules27196203"]}}], "PubmedBookArticle": []}